{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:03:02Z","timestamp":1789052582772,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003359","name":"Generalitat of Valencia","doi-asserted-by":"publisher","award":["CIPROM\/2022\/45"],"award-info":[{"award-number":["CIPROM\/2022\/45"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat of Valencia","doi-asserted-by":"publisher","award":["CIGE\/2023\/073"],"award-info":[{"award-number":["CIGE\/2023\/073"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Spain Ministry of Science Innovation and Universities","doi-asserted-by":"publisher","award":["PID2023-152677OB-I00"],"award-info":[{"award-number":["PID2023-152677OB-I00"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI21-00220"],"award-info":[{"award-number":["PI21-00220"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI25-01315"],"award-info":[{"award-number":["PI25-01315"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CD22\/00045"],"award-info":[{"award-number":["CD22\/00045"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108321","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:21:17Z","timestamp":1782314477000},"page":"108321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Tirzepatide, a dual GIP\/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE\u2212\/\u2212 mice"],"prefix":"10.1016","volume":"230","author":[{"given":"\u00c1lvaro","family":"G\u00f3mez-Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-1727","authenticated-orcid":false,"given":"Patrice","family":"Marques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Arce-Recatal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Vea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-6954","authenticated-orcid":false,"given":"Blanca","family":"Alabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 T.","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Jes\u00fas","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8010-5168","authenticated-orcid":false,"given":"Laura","family":"Piqueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.anclin.2022.08.010","article-title":"Abdominal aortic aneurysms (etiology, epidemiology, and natural history)","volume":"40","author":"Calgi","year":"2022","journal-title":"Anesthesiol. Clin."},{"issue":"16","key":"10.1016\/j.phrs.2026.108321_bib2","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.108.817619","article-title":"Risk factors for abdominal aortic aneurysms: a 7-year prospective study: the Troms\u00f8 Study, 1994-2001","volume":"119","author":"Forsdahl","year":"2009","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2026.108321_bib3","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1378\/chest.108.6.1758","article-title":"Intermittent cocaine use associated with recurrent dissection of the thoracic and abdominal aorta","volume":"108","author":"Chang","year":"1995","journal-title":"Chest"},{"issue":"29","key":"10.1016\/j.phrs.2026.108321_bib4","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1093\/eurheartj\/ehad386","article-title":"Pathogenesis and management of abdominal aortic aneurysm","volume":"44","author":"Golledge","year":"2023","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/biom12040509","article-title":"Endothelial dysfunction in the pathogenesis of abdominal aortic aneurysm","volume":"12","author":"DeRoo","year":"2022","journal-title":"Biomolecules"},{"issue":"28","key":"10.1016\/j.phrs.2026.108321_bib6","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.2174\/1381612821666150826094156","article-title":"The role of endothelial dysfunction in aortic aneurysms","volume":"21","author":"Siasos","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.phrs.2026.108321_bib7","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrcardio.2017.52","article-title":"Monocytes and macrophages in abdominal aortic aneurysm","volume":"14","author":"Raffort","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108321_bib8","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s11906-004-0038-0","article-title":"Angiotensin II and abdominal aortic aneurysms","volume":"6","author":"Daugherty","year":"2004","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.phrs.2026.108321_bib9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.freeradbiomed.2020.02.002","article-title":"Angiotensin II and leukocyte trafficking: New insights for an old vascular mediator. Role of redox-signaling pathways","volume":"157","author":"Piqueras","year":"2020","journal-title":"Free. Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.phrs.2026.108321_bib10","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1172\/JCI7818","article-title":"Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice","volume":"105","author":"Daugherty","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108321_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1749-6632.1999.tb07789.x","article-title":"Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor -\/- mice","volume":"892","author":"Daugherty","year":"1999","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"6","key":"10.1016\/j.phrs.2026.108321_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How May GIP Enhance the Therapeutic Efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol. Metab."},{"issue":"10160","key":"10.1016\/j.phrs.2026.108321_bib13","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2026.108321_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/dom.14553","article-title":"The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis","volume":"24","author":"Wilson","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib18","article-title":"Evaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure","volume":"17","author":"Bin Abdul Malik","year":"2025","journal-title":"Cureus"},{"issue":"11","key":"10.1016\/j.phrs.2026.108321_bib19","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1172\/JCI107470","article-title":"Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria","volume":"52","author":"Jaffe","year":"1973","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108321_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1154158","article-title":"CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction","volume":"14","author":"Hueso","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.phrs.2026.108321_bib21","first-page":"137","article-title":"Cell-cell adhesive interactions in an in vitro flow chamber","volume":"96","author":"Goetz","year":"1999","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.phrs.2026.108321_bib22","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-62703-128-8_18","article-title":"Studying leukocyte recruitment under flow conditions","volume":"946","author":"Parsons","year":"2013","journal-title":"Methods Mol. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108321_bib23","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.4049\/jimmunol.162.10.6209","article-title":"Mechanisms of selective leukocyte recruitment from whole blood on cytokine-activated endothelial cells under flow conditions","volume":"162","author":"Patel","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2026.108321_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"issue":"10","key":"10.1016\/j.phrs.2026.108321_bib25","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/dom.14110","article-title":"The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists","volume":"22","author":"Urva","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"27","key":"10.1016\/j.phrs.2026.108321_bib26","first-page":"1291","article-title":"Measuring blood pressure in mice using volume pressure recording, a tail-cuff method","author":"Daugherty","year":"2009","journal-title":"J. Vis. Exp."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/sj.bjp.0704331","article-title":"Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis","volume":"134","author":"Daugherty","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108321_bib28","first-page":"439","article-title":"Guidelines and Considerations for Metabolic Tolerance Tests in Mice. Diabetes Metab Syndr Obes","volume":"13","author":"Bened\u00e9-Ubieto","year":"2020"},{"issue":"11","key":"10.1016\/j.phrs.2026.108321_bib29","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1172\/JCI31311","article-title":"Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice","volume":"117","author":"Sun","year":"2007","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108321_bib30","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2164-10-298","article-title":"Whole genome expression analysis within the angiotensin II-apolipoprotein E deficient mouse model of abdominal aortic aneurysm","volume":"10","author":"Rush","year":"2009","journal-title":"BMC Genom."},{"issue":"3","key":"10.1016\/j.phrs.2026.108321_bib31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/CS20080196","article-title":"Role of TNF-alpha in vascular dysfunction","volume":"116","author":"Zhang","year":"2009","journal-title":"Clin. Sci. (Lond. )"},{"issue":"3","key":"10.1016\/j.phrs.2026.108321_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3390\/cells13030274","article-title":"Cellular, Molecular and Clinical Aspects of Aortic Aneurysm-Vascular Physiology and Pathophysiology","volume":"13","author":"Domaga\u0142a","year":"2024","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.phrs.2026.108321_bib33","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1111\/bph.13098","article-title":"Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE(-\/-) mice and angiogenesis","volume":"172","author":"Escudero","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108321_bib34","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1161\/ATVBAHA.116.307530","article-title":"Vitamin D Receptor Activation Reduces Angiotensin-II-Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E-Knockout Mice","volume":"36","author":"Martorell","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108321_bib35","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial","volume":"327","author":"Dahl","year":"2022","journal-title":"Jama"},{"issue":"10313","key":"10.1016\/j.phrs.2026.108321_bib36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.phrs.2026.108321_bib37","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jama.2023.20294","article-title":"Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial","volume":"330","author":"Rosenstock","year":"2023","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib38","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11897-025-00704-1","article-title":"Therapeutic Potential of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction (HFpEF) in Obese Patients","volume":"22","author":"Patel","year":"2025","journal-title":"Curr. Heart Fail. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2026.108321_bib39","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/cvr\/cvaf005","article-title":"Glucose-dependent insulinotropic polypeptide\/glucagon-like peptide 1 receptor agonist tirzepatide promotes branched chain amino acid catabolism to prevent myocardial infarction in non-diabetic mice","volume":"121","author":"Chen","year":"2025","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108321_bib40","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108321_bib41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib42","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12933-025-02806-5","article-title":"Tirzepatide, a dual GIP\/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide","volume":"24","author":"Heged\u0171s","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"issue":"11-12","key":"10.1016\/j.phrs.2026.108321_bib43","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1089\/hum.2019.124","article-title":"Pro-Renin Receptor Overexpression Promotes Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-Knockout Mice","volume":"31","author":"Ma","year":"2020","journal-title":"Hum. Gene Ther."},{"issue":"13","key":"10.1016\/j.phrs.2026.108321_bib44","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1093\/cvr\/cvy135","article-title":"Functional role of endothelial CXCL16\/CXCR6-platelet-leucocyte axis in angiotensin II-associated metabolic disorders","volume":"114","author":"Collado","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035683","article-title":"Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice","volume":"7","author":"Nogi","year":"2012","journal-title":"PLoS. One"},{"issue":"7","key":"10.1016\/j.phrs.2026.108321_bib46","doi-asserted-by":"crossref","first-page":"832","DOI":"10.3390\/biomedicines9070832","article-title":"Glucose-Dependent Insulinotropic Polypeptide Suppresses Foam Cell Formation of Macrophages through Inhibition of the Cyclin-Dependent Kinase 5-CD36 Pathway","volume":"9","author":"Terasaki","year":"2021","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.phrs.2026.108321_bib47","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","article-title":"SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice","volume":"39","author":"Ortega","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1155\/2009\/352319","article-title":"A systematic review of studies examining inflammation associated cytokines in human abdominal aortic aneurysm samples","volume":"26","author":"Golledge","year":"2009","journal-title":"Dis. Markers"},{"issue":"3","key":"10.1016\/j.phrs.2026.108321_bib49","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jvs.2006.11.020","article-title":"The pro-inflammatory and chemotactic cytokine microenvironment of the abdominal aortic aneurysm wall: a protein array study","volume":"45","author":"Middleton","year":"2007","journal-title":"J. Vasc. Surg."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib50","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jvs.2025.11.021","article-title":"Glucagon-like peptide-1 receptor agonists are associated with reduced abdominal aortic aneurysm-related events","volume":"83","author":"Ahn","year":"2026","journal-title":"J. Vasc. Surg."},{"issue":"5","key":"10.1016\/j.phrs.2026.108321_bib51","doi-asserted-by":"crossref","first-page":"E895","DOI":"10.1152\/ajpendo.00511.2018","article-title":"Antiatherogenic effects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase-independent mechanisms","volume":"316","author":"Koshibu","year":"2019","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2026.108321_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jacbts.2022.08.002","article-title":"Liraglutide Lowers Endothelial Vascular Cell Adhesion Molecule-1 in Murine Atherosclerosis Independent of Glucose Levels","volume":"8","author":"Punjabi","year":"2023","journal-title":"JACC Basic. Transl. Sci."},{"key":"10.1016\/j.phrs.2026.108321_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.07.014","article-title":"Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress","volume":"264","author":"Yang","year":"2017","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.phrs.2026.108321_bib54","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-\/-) and LDLr(-\/-) Mice by a Mechanism That Includes Inflammatory Pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic. Transl. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2026.108321_bib55","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108321_bib56","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molmet.2018.05.014","article-title":"The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE(-\/-) mice by blocking monocyte\/macrophage activation","volume":"14","author":"Kahles","year":"2018","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension","volume":"40","author":"Helmst\u00e4dter","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108321_bib58","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","article-title":"Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies","volume":"30","author":"Malavazos","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib59","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00125-009-1643-x","article-title":"Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells","volume":"53","author":"Hadjiyanni","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108321_bib60","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib61","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2337\/db15-0122","article-title":"Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB","volume":"65","author":"Berglund","year":"2016","journal-title":"Diabetes"},{"issue":"22","key":"10.1016\/j.phrs.2026.108321_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153732","article-title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","volume":"6","author":"McLean","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2026.108321_bib63","doi-asserted-by":"crossref","first-page":"12077","DOI":"10.2147\/DDDT.S563581","article-title":"Therapeutic Targeting of Signaling Pathways in Abdominal Aortic Aneurysm: From Pathogenesis to Precision Medicine","volume":"19","author":"Shaikh","year":"2025","journal-title":"Drug. Des. Devel Ther."},{"issue":"2","key":"10.1016\/j.phrs.2026.108321_bib64","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2026.108321_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2024.171245","article-title":"Tirzepatide protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress and inflammation via PI3K\/Akt signaling","volume":"178","author":"Chen","year":"2024","journal-title":"Peptides"},{"issue":"5","key":"10.1016\/j.phrs.2026.108321_bib66","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10557-023-07456-x","article-title":"Glucagon-Like Peptide-1 Inhibits the Progression of Abdominal Aortic Aneurysm in Mice: The Earlier, the Better","volume":"38","author":"Zhao","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"4","key":"10.1016\/j.phrs.2026.108321_bib67","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1078-5884(96)80183-3","article-title":"Angiogenesis in abdominal aortic aneurysms","volume":"11","author":"Thompson","year":"1996","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"issue":"2","key":"10.1016\/j.phrs.2026.108321_bib68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/jsre.2002.6468","article-title":"Expression of angiogenesis and angiogenic factors in human aortic vascular disease","volume":"106","author":"Kobayashi","year":"2002","journal-title":"J. Surg. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib69","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12933-023-01797-5","article-title":"Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program","volume":"22","author":"Lingvay","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108321_bib70","doi-asserted-by":"crossref","first-page":"H1660","DOI":"10.1152\/ajpheart.00028.2009","article-title":"ANG II infusion promotes abdominal aortic aneurysms independent of increased blood pressure in hypercholesterolemic mice","volume":"296","author":"Cassis","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib71","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"21","key":"10.1016\/j.phrs.2026.108321_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.phrs.2026.108321_bib73","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation","volume":"27","author":"Dai","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib74","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.2310\/6670.2008.00092","article-title":"Gender differences in abdominal aortic aneurysms","volume":"17","author":"Hannawa","year":"2009","journal-title":"Vascular"},{"issue":"11","key":"10.1016\/j.phrs.2026.108321_bib75","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1161\/01.ATV.0000143386.26399.84","article-title":"Gender differences in experimental aortic aneurysm formation","volume":"24","author":"Ailawadi","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108321_bib76","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1191\/1358863x02vm413ra","article-title":"Abdominal aortic aneurysms: fresh insights from a novel animal model of the disease","volume":"7","author":"Manning","year":"2002","journal-title":"Vasc. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:05:25Z","timestamp":1785895525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":76,"alternative-id":["S1043661826002367"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108321","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide, a dual GIP\/GLP-1 receptor agonist, attenuates endothelial dysfunction and angiotensin II-induced abdominal aortic aneurysm in ApoE\u2212\/\u2212 mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108321","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108321"}}